Details of Disease

General Information of Disease (ID: DISGXZ2Q)

• Disease Name: Mammary analogue secretory carcinoma
• Synonyms: juvenile carcinoma (formerly); SBC; JSCB; secretory carcinoma of the breast; secretory carcinoma of breast; secretory carcinoma; secretory breast carcinoma; juvenile secretory carcinoma of the breast; juvenile secretory carcinoma of breast; juvenile secretory breast carcinoma; juvenile carcinoma of the breast (morphologic abnormality); juvenile carcinoma of the breast; juvenile carcinoma of breast; juvenile breast carcinoma; invasive cystic hypersecretory duct breast carcinoma; infiltrating cystic hypersecretory duct breast carcinoma; cystic hypersecretory carcinoma of the breast; cystic hypersecretory carcinoma of breast; cystic hypersecretory breast carcinoma
• Disease Class: 2C60-2C6Y: Breast cancer
• Definition: A rare, low grade invasive adenocarcinoma of the breast characterized by the presence of cells that secrete milk-like material. Morphologically, it usually appears as a circumscribed lesion, composed of cystic spaces, tubular structures, and solid areas.
• Disease Hierarchy:
  DIS43J58: Invasive ductal breast carcinoma
  DISGXZ2Q: Mammary analogue secretory carcinoma
• ICD Code: ICD-11: ICD-11: 2C60
• Disease Identifiers:
  MONDO ID: MONDO_0003208
  MESH ID: C537535
  UMLS CUI: C0334371
  MedGen ID: 87226
  SNOMED CT ID: 41919003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Entrectinib	DMMPTLH	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
NTRK3	TTXABCW	Disputed	Biomarker	[2]
CD6	TTMF6KC	Strong	Biomarker	[3]

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BHLHA15	OTY7IER8	Strong	Altered Expression	[4]
MAML3	OTZFV53Z	Strong	Biomarker	[5]
TPM3	OT5RU5G6	Strong	Biomarker	[6]

References

• [1] Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
• [2] Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.Histopathology. 2020 Feb;76(3):375-382. doi: 10.1111/his.13981. Epub 2019 Dec 11.
• [3] Secretory Carcinoma of the Skin: Report of 6 Cases, Including a Case With a Novel NFIX-PKN1 Translocation.Am J Surg Pathol. 2019 Aug;43(8):1092-1098. doi: 10.1097/PAS.0000000000001261.
• [4] Mist1: a novel nuclear marker for acinic cell carcinoma of the salivary gland.Virchows Arch. 2019 Nov;475(5):617-624. doi: 10.1007/s00428-019-02600-1. Epub 2019 Jun 11.
• [5] Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.Hum Pathol. 2019 Jan;83:50-58. doi: 10.1016/j.humpath.2018.08.011. Epub 2018 Aug 18.
• [6] Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.Histopathology. 2019 Jul;75(1):54-62. doi: 10.1111/his.13845. Epub 2019 May 16.